• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    UFP Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    7/1/24 11:38:44 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care
    Get the next $UFPT alert in real time by email
    Form 8-K
    0000914156 False 0000914156 2024-06-27 2024-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  June 27, 2024

    _______________________________

    UFP Technologies, Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware 001-12648 04-2314970
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

    100 Hale Street

    Newburyport, Massachusetts - USA 01950-3504

    (Address of Principal Executive Offices) (Zip Code)

    (978) 352-2200

    (Registrant's telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock UFPT The NASDAQ Stock Market L.L.C.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 1.01. Entry into a Material Definitive Agreement.

    UFP Technologies, Inc. (“UFP” or the “Company”) entered into the following agreement in connection with the completion of its acquisition of AJR Enterprises, LLC, a Delaware limited liability company (“AJR”):

    Securities Purchase Agreement

    On July 1, 2024, pursuant to the terms of a Securities Purchase Agreement, dated as of July 1, 2024 (the “Purchase Agreement”), by and among AJR Enterprises, LLC, a Delaware limited liability company and its purchase price beneficiaries (collectively the “Sellers”), and the Company, the Company purchased from the Sellers all of the issued and outstanding membership interests of AJR Enterprises, LLC for an aggregate purchase price of $110 million in cash. The purchase price is subject to adjustment based upon AJR’s working capital at closing.

    $4 million of the purchase price is being held in escrow to indemnify the Company against certain claims, losses and liabilities. The Purchase Agreement contains customary representations, warranties and covenants customary for transactions of this type. As part of the Securities Purchase Agreement, the Sellers as well as certain restricted parties have agreed to not compete with the Company for a period of seven years.

    The above description of the Purchase Agreement is qualified in its entirety by reference to the Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

    Amended and Restated Credit Agreement

    On June 27, 2024, the Company, as the borrower, entered into a secured $275 million Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with certain of the Company’s subsidiaries (the “Subsidiary Guarantors”) and Bank of America, N.A., in its capacity as the initial lender, Administrative Agent, Swingline Lender and L/C Issuer, and certain other lenders from time-to-time party thereto. The Amended and Restated Credit Agreement amends and restates the Company’s prior credit agreement, originally dated as of December 22, 2001. Our new credit agreement increases the size of our credit facility, extends its maturity, changes the interest we pay should our leverage ratio exceed 3X and adds new permitted acquisitions we may close, among other things.

    The credit facilities under the Amended and Restated Credit Agreement consist of a secured term loan to UFP of up to $125 million and a secured revolving credit facility, under which the Company may borrow up to $150 million.  The Amended and Restated Credit Facilities mature on June 27, 2029. This maturity date is subject to acceleration and the Company could be subject to additional fees and expenses in certain circumstances should one or more events of default described in the Amended and Restated Credit Agreement occur. The proceeds of the Amended and Restated Credit Agreement may be used for general corporate purposes, including funding the acquisition of AJR Enterprises, LLC, as well as certain other permitted acquisitions.

    The Company’s obligations under the Amended and Restated Credit Agreement are guaranteed by the Subsidiary Guarantors.

    The Amended and Restated Credit Facilities call for interest of SOFR plus a margin that ranges from 1.25% to 2.25% or, at the discretion of the Company, the bank’s prime rate plus a margin that ranges from .25% to 1.25%. In both cases the applicable margin is dependent upon Company performance. Under the Amended and Restated Credit Agreement, the Company is subject to a minimum fixed-charge coverage financial covenant as well as a maximum total funded debt to EBITDA financial covenant. The Amended and Restated Credit Agreement contains other covenants customary for transactions of this type, including restrictions on certain payments, permitted indebtedness and permitted investments. 

    As of July 1, 2024, the Company had approximately $150 million in borrowings outstanding under the Amended and Restated Credit Facilities, $115 million of which was under its secured term loan and was used as consideration for the AJR acquisition and $35 million of which was under its revolving credit facility, which the Company rolled over from its former facility. As of July 1, 2024, after reducing the available amount by certain letters of credit, the Company has $114 million available to draw under its revolving credit facility. As of July 1, 2024, until December 31, 2024, the Company may draw up to an additional $10 million of borrowing under its secured term loan.

    The above description of the Amended and Restated Credit Agreement is qualified in its entirety by reference to the Amended and Restated Credit Agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K.

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information regarding the Amended and Restated Credit Agreement, as set forth in Item 1.01 of this Form 8-K, is hereby incorporated by reference into this Item 2.03.

    Item 7.01. Regulation FD Disclosure.

    Located in St. Charles, Illinois with manufacturing capabilities in Santiago, Dominican Republic, AJR Enterprises, LLC is a medical device contract manufacturer specializing in the design, development and manufacturing of single use patient safe handling medical devices. For the trailing 12 months ended March 31, 2024, AJR Enterprises LLC had sales of approximately $75 million to a single, major customer in the safe patient handling space. Excluding transaction costs and working capital adjustments, the Company paid $110 million in connection with the acquisition of AJR. The aggregate estimated purchase price is approximately 6.5 times AJR’s 2023 adjusted net income before interest, taxes, depreciation and amortization (adjusted EBITDA). The Company defines AJR’s estimated adjusted EBITDA, which is a non-GAAP financial measure, as adjusted net income plus net interest expense, income taxes, and depreciation and amortization expense. The Company defines AJR’s adjusted net-income as net income, plus or minus one-time items contained in AJR’s 2023 results.

    On July 1, 2024 UFP issued a press release relating to the completion of the Company’s acquisition of AJR Enterprises, LLC.  The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

    Limitation on Incorporation by Reference.  The information furnished in this Item 7.01, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements.  Please refer to the cautionary note in the press release regarding these forward-looking statements.

    Item 9.01. Financial Statements and Exhibits.

    (a) Exhibits. 

    Exhibit Number   Description
         
    10.1   Securities Purchase Agreement, dated as of July 1, 2024, by and among AJR Enterprises, LLC, a limited liability company and its purchase price beneficiaries and UFP Technologies, Inc.    
    10.2*   Amended and Restated Credit Agreement, dated June 27, 2024, between and among UFP Technologies, Inc., certain of its subsidiaries as guarantors and Bank of America, N.A., in its capacity as the initial lender, Administrative Agent, Swingline Lender and L/C Issuer    
    99.1   Press release dated July 1, 2024 of UFP Technologies, Inc. announcing the completion of its acquisition of AJR Enterprises, LLC.

    * Pursuant to Item 601(b)(10) of Regulation S-K, certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Further, the schedules  to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule  will be furnished to the Securities and Exchange Commission upon request.

     
     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

      UFP Technologies, Inc.
         
       
    Date: July 1, 2024 By:  /s/ Ronald J. Lataille        
        Ronald J. Lataille
        Chief Financial Officer and Senior Vice President
       

     

    Get the next $UFPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UFPT

    DatePrice TargetRatingAnalyst
    3/28/2025Mkt Perform
    Raymond James
    7/17/2024$344.00 → $392.00Buy
    Lake Street
    3/20/2024Market Outperform
    CJS Securities
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    12/21/2022$124.00Buy
    Lake Street
    6/22/2022$110.00Buy
    Lake Street
    11/19/2021$81.00Buy
    Colliers Securities
    More analyst ratings

    $UFPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on UFP Technologies

    Raymond James initiated coverage of UFP Technologies with a rating of Mkt Perform

    3/28/25 8:21:18 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Lake Street reiterated coverage on UFP Technologies with a new price target

    Lake Street reiterated coverage of UFP Technologies with a rating of Buy and set a new price target of $392.00 from $344.00 previously

    7/17/24 8:57:19 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    CJS Securities initiated coverage on UFP Technologies

    CJS Securities initiated coverage of UFP Technologies with a rating of Market Outperform

    3/20/24 9:43:53 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UFP Technologies Announces CEO Succession Plan

    NEWBURYPORT, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that R. Jeffrey Bailly will retire as CEO at the Company's next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company's Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. "Serving as CEO for 31 years, Jeff has been an extremely effective leader who, together with his team, transitioned the company to a leading g

    12/2/25 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 37th Annual Healthcare Conference

    NEWBURYPORT, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT) a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly, President Mitchell C. Rock, and Chief Financial Officer Ron Lataille will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference to be held in New York City December 1-4, 2025. UFP's presentation is scheduled to begin at 8:10 AM on Wednesday, December 3rd. A live audio webcast of UFP's presentation will be available here. About UFP Technologies, Inc.UFP Technologies is a contract deve

    11/25/25 4:10:00 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Announces Strong Q3 2025 Results

    NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per dilute

    11/3/25 4:08:33 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bailly R Jeffrey was granted 1,744 shares and covered exercise/tax liability with 888 shares, increasing direct ownership by 0.56% to 153,096 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    12/22/25 4:24:25 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Vice President Holt Jason sold $21,358 worth of shares (100 units at $213.58), decreasing direct ownership by 1% to 7,678 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    12/12/25 1:26:28 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Vice President Holt Jason gifted 70 shares, decreasing direct ownership by 0.89% to 7,778 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    12/11/25 5:28:28 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    SEC Filings

    View All

    $UFPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by UFP Technologies Inc.

    SCHEDULE 13G/A - UFP TECHNOLOGIES INC (0000914156) (Subject)

    2/6/26 1:22:31 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)

    12/2/25 8:31:01 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)

    12/2/25 8:27:24 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Lataille Ronald J bought $91,636 worth of shares (400 units at $229.09), increasing direct ownership by 3% to 15,031 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    2/27/25 3:57:17 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Lataille Ronald J

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    11/13/23 11:09:49 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Rock Mitchell bought $27,522 worth of shares (198 units at $139.00), increasing direct ownership by 0.74% to 27,086 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    11/9/23 5:21:17 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Financials

    Live finance-specific insights

    View All

    UFP Technologies Announces Strong Q3 2025 Results

    NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per dilute

    11/3/25 4:08:33 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies to Report Third Quarter 2025 Financial Results on November 3, 2025

    NEWBURYPORT, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the third quarter on Monday, November 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, November 4th, at 8:30 AM Eastern time. Conference Call Information:Date: Tuesday, November 4, 2025Time: 8:30 AM Eastern Time Participants may join the call using the following dial-in numbers: USA/Canada: Toll-Free: 1-412-206-6478International: 1-833-890-4

    10/29/25 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Announces Record Q2 Results

    NEWBURYPORT, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its second quarter ended June 30, 2025, compared to net income of $13.6 million or $1.75 per diluted common share outstanding for the same quarter in 2024. Adjusted earnings per diluted common share outstanding grew 27% to $2.50. Sales for the second quarter were $151.2 million compared to sales of $110.2 million in the second quarter of 2024. Net income for the six-month period ended June

    8/4/25 4:15:31 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Leadership Updates

    Live Leadership Updates

    View All

    UFP Technologies Acquires AQF Medical

    NEWBURYPORT, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of AQF Limited ("AQF Medical"). Headquartered in Navan, Ireland with additional joint venture operations in Singapore, AQF Medical develops and manufactures custom-engineered foam and thermoplastic components used in a wide range of medical devices and packaging. "We are excited about the addition of AQF Medical, our fourth acquisition in the past few months," said R. Jeffrey Bailly, Chairman and CEO of UFP Technologies.

    8/26/24 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Acquires Marble Medical

    NEWBURYPORT, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of Marble Medical. Founded in 1988 and headquartered in Tallahassee, FL, Marble Medical develops and manufactures adhesive based medical components and single-use devices. "Adding Marble Medical's adhesives expertise is a great complement to our surgical robot drapes and stick to skin device platforms," said R. Jeffrey Bailly, chairman and CEO of UFP Technologies. "Marble Medical is a 3M Preferred Converter, and along wi

    7/16/24 4:05:00 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Chimerix Appoints Marc D. Kozin to Board of Directors

    DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

    3/21/24 7:00:00 AM ET
    $CMRX
    $UFPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $UFPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by UFP Technologies Inc.

    SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

    11/13/24 9:58:23 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by UFP Technologies Inc. (Amendment)

    SC 13G/A - UFP TECHNOLOGIES INC (0000914156) (Subject)

    3/8/24 3:02:25 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by UFP Technologies Inc.

    SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

    2/13/24 5:16:09 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care